Abstract: The devices and methods described herein push forward the resolution limits of directed self-assembly (DSA) technology for advanced device applications. Specifically described herein, are compositions of bioinspired DSA materials and methods using these bioinspired DSA materials to form sub-7 nm line-space patterns and to achieve functional nanoscopic structures, e.g., conducting nanowires on a substrate.

Abstract: The present invention relates to antibodies targeted to BDCA2 that deplete plasmacytoid dendritic cells (pDC) and methods of using the antibodies to treat disorders associated with pDC.

Abstract: Provided herein according to some embodiments is a biocompatible scaffold comprising stem cells (e.g., a pliable scaffold) suitable for intracavity administration after surgical removal of a tumor, wherein the scaffold allows the stem cells to migrate away from the scaffold and towards a cancerous or damaged tissue, wherein the stem cells are loaded with a therapeutic agent and/or a reporter molecule. Methods of forming the scaffold, and methods of use thereof, are also provided.

Abstract: Decoding methods are provided for identifying populations in assays, particularly multiplexing assays and those associated with fluidic devices.

Abstract: Disclosed herein are unique single stranded DNA oligonucleotide products identified as binding with high affinity and specificity to ovarian tumor cells that may be used in the delivery of therapy to and diagnosis of ovarian cancer.

Abstract: The present disclosure is concerned with benzo annulene compounds that are capable of inhibiting a Mer tyrosine kinase and/or a Tyro3 tyrosine kinase and methods of treating a bacterial infection, a viral infection, and/or a disorder of uncontrolled cellular proliferation such as, for example, a cancer, using these compounds. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Abstract: Methods of forming a chip with fluidic channels include forming (e.g., milling) at least one nanofunnel with a wide end and a narrow end into a planar substrate, the nanofunnel having a length, with width and depth dimensions that both vary over its length and forming (e.g., milling) at least one nanochannel into the planar substrate at an interface adjacent the narrow end of the nanofunnel.

Abstract: Systems and related methods for stationary digital chest tomosynthesis (s-DCT) imaging are disclosed. In some aspects, systems include a stationary x-ray source array with an array of x-ray pixels configured to generate x-ray beams at different viewing angles relative to a subject to be imaged that is stationary, a stationary area x-ray detector configured to record x-ray projection images of the subject, a physiological gating apparatus for monitoring at least one physiological signal of the subject and defining a physiological phase and a time window based on the at least one physiological signal, and a computing platform configured to activate the x-ray pixels based on the physiological phase and the time window and upon receipt of the at least one physiological signal from the physiological gating apparatus in order to synchronize x-ray exposure with the at least one physiological signal of the subject.

Abstract: Apparatuses including power electronics circuitry are provided. The power electronics circuitry includes at least one power converter that is coupled to a DC bus. Moreover, in some embodiments, the at least one power converter is configured to regulate a voltage of the DC bus. Related methods of operating an apparatus including power electronics circuitry are also provided.

Abstract: This invention relates generally to compounds that are glucuronidase inhibitors. The glucuronidase inhibitors include phenoxy thiophene sulfonamides, and other compounds such as pyridine sulfonyls, benzene sulfonyls, thiophene sulfonyls, thiazole sulfonyls, thiophene carbonyls, and thiazole carbonyls. These compounds include nialamide, isocarboxazid, phenelzine, amoxapine, loxapine and mefloquine. Also compositions including one or more of such compounds for use in inhibiting glucuronidase and methods of using one or more of such compounds for selective inhibition of bacterial ?-glucoronidase. These compounds may be used as a co-drug in combination with the anticancer drug CPT-11. Also a method for screening compounds to determine their usefulness in reducing diarrhea associated with irinotecan chemotherapy.

Abstract: Disclosed herein are devices, apparatuses and methods for generating self-sustaining gaseous and non-gaseous gradients across a cell support structure and for culturing one or more cells or tissues under hypoxic conditions. Methods of generating one or more gas gradients across a cell support structure include providing a luminal container having a bottom wall that is a gas permeable membrane, positioning a cell support structure above the bottom wall, positioning one or more cells or tissues on the cell support structure, and generating one or more gas gradients between the bottom wall, across the cell support structure and into a luminal reservoir. An apparatus to produce hypoxic conditions for cell cultures includes a luminal container having a bottom wall, a cell support structure on the bottom wall, and a cover that sealably closes the open top, such that a hypoxic condition can be generated in the luminal reservoir.

Abstract: In some aspects, the present disclosure provides compounds of the formula: wherein the variables are as defined herein. In some embodiments, these compounds may be used to reduce the pain of a patient. These compounds may be used in pain relief and show an improved pharmaceutical profile relative to other commonly used opiates and opioid derivatives.

Abstract: The present invention provides a polyploid adeno-associated virus (AAV) capsid, wherein the capsid comprises capsid protein VP1, wherein said capsid protein VP1 is from one or more than one first AAV serotype, wherein said capsid protein VP2 is from one or more than one first AAV serotype and capsid protein VP3, wherein said capsid protein VP3 is from one or more than one second AAV serotype and wherein at least one of said first AAV serotype is different from at least one of said second AAV serotype and is different from at least one of said third AAV serotype, in any combination.

Abstract: Methods and compositions are provided for determining a subtype of lung adenocarcinoma (AD) of an individual by detecting the expression level of at least one classifier biomarker selected from a group of gene signatures for lung adenocarcinoma. Also provided herein are methods and compositions for determining the response of an individual with an adenocarcinoma subtype to a therapy such as immunotherapy.

Abstract: A miniature electrode apparatus is disclosed for trapping charged particles, the apparatus includes, along a longitudinal direction, a first end cap electrode, a central electrode having an aperture, and a second end cap electrode. The aperture is elongated in the lateral plane and extends through the central electrode along the longitudinal direction and the central electrode surrounds the aperture in a lateral plane perpendicular to the longitudinal direction to define a transverse cavity for trapping charged particles. Electric fields can be applied in a y-direction of the lateral plane across one or more planes perpendicular to the longitudinal axis to translocate and/or manipulate ion trajectories.

Abstract: Provided herein, in some embodiments, are compositions of Zika-specific antibodies and antigen-binding fragments thereof and methods of using said antibodies and antigen-binding fragments.

Abstract: Described herein, inter alia, are compositions and methods for modulating mu opioid receptor activity.

Abstract: The present invention relates to a method of treating, mitigating, minimizing, or preventing HIV-1/AIDS by administering a CD24 protein to a subject in need thereof. Also provided herein is use of a CD24 protein in the manufacture of a medicament for treating HIV-1/AIDS. Further, provided is a pharmaceutical composition comprising a pharmaceutically acceptable amount of a CD24 protein.

Abstract: This invention relates generally to the use of 5?-methylthioadenosine phosphorylase (MTAP) inhibitors for the treatment of lung diseases associated with inflammation, such as cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD). Small molecule inhibitors of MTAP can sustain accumulation of endogenous MTA to therapeutically beneficial levels resulting in decreased inflammation in CF and COPD.

Abstract: A flow cell is provided that includes surface-attached structures in a chamber. The structures are movable in response to a magnetic or electric field. A target extraction or isolation system includes the flow cell and a driver configured for applying a magnetic or electric field to the interior of the flow cell to actuate movement of the structures. The flow cell may be utilized to extract or isolate a target from a sample flowing through the flow cell. Further, a microfluidic system is provided that includes surface-attached structures and a microarray, wherein actuated motion of the surface-attached structures is used to enhance flow, circulation, and/or mixing action for analyte capture on the microarray.